| Ref ID | 400 |
| First Author | D. H. Odierna |
| Journal | JOURNAL OF CLINICAL EPIDEMIOLOGY |
| Year Of Publishing | 2009 |
| URL | https://www.jclinepi.com/article/S0895-4356(09)00030-4/fulltext |
| Keywords |
• Equity • Pharmacological |
| Problem(s) |
• Failure to consider equity, different socioeconomic groups or disadvantaged populations |
| Article Type | Empirical |
| Article Subtype | Cross-sectional survey/Methodological systematic review |
| First Author Country | United States |
| Aim | To assess racial/ethnic, gender, and socioeconomic status concordance between Medicaid populations and studies synthesized in Drug Effectiveness Review Project systematic reviews. |
| Level of Investigation | Descriptive |
| Summary of Findings | Among Medicaid recipients, minorities are overrepresented (21% to 57%) compared with their presence in the US population (10% to 30%). 59% of included Drug Effectiveness Review Project systematic reviews reported insufficient evidence to evaluate drug effects by race/ethnicity or gender. 3% of reviews found evidence of differential effects by race and 13% by gender. 24% found evidence of no difference by race and 9% found no difference by gender. Most of this evidence was described as weak, limited, or of poor quality. Most DERP reviews reported insufficient evidence for any analysis of differential effects in subgroups defined by gender or race/ethnicity. Evidence should be collected and analysed in ways that allow policymakers to develop policies that support health equity in disadvantaged populations. Low-SES individuals should be an included subgroup in systematic reviews. |
| Number of systematic reviews included | 32 |
| Number of eligible systematic reviews assessed | 32 |
| Treatment impacted | No |
| Treatment impacted description | |
| Interpretation impacted | Not Applicable |
| Interpretation impacted description |